• 
  Daniel Ontaneda, MD, PhD, a staff member of the Cleveland Clinic Mellen Center for Multiple Sclerosis, who gave an overview on the new 2024 McDonald criteria to diagnose multiple sclerosis (MS), which was presented at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). 
  • Check out the full episode here: https://www.neurologylive.com/view/episode-125-understanding-major-changes-new-mcdonald-criteria-multiple-sclerosis
    
  
  
  


• 
  Ian Kremer, executive director of the leaders Engaged on Alzheimer's Disease (LEAD) coalition, on the changing and exciting advances in Alzheimer disease therapeutics, as well as the discontinuation of aducanumab, the first approved antiamyloid therapy. 
  • Check out the full episode here: https://www.neurologylive.com/view/episode-113-lessons-learned-alzheimer-drug-development
    
  
  
  


• 
  Andy Berkowski, MD, PhD, vice chair of the American Academy of Sleep Medicine's Practice Guidelines Task Force, discusses the newly revised guidelines for restless legs syndrome, including the latest updates in literature and changes to clinical care. 
  • Check out the full episode here: https://www.neurologylive.com/view/episode-129-implications-2024-aasm-guidelines-restless-legs-syndrome
    
  
  
  


• 
  Sameea Husain-Wilson, DO, a movement disorder specialist at the Marcus Neuroscience Institute of Baptist Health, provided clinical perspective on the use of the Syn-One diagnostic test for patients with Parkinson disease.
  • Check out the full episode here: https://www.neurologylive.com/view/episode-119-utilizing-the-syn-one-test-to-diagnose-parkinson-disease
    
  
  
  


• 
  Jonathan Parker, MD, PhD, an assistant professor of neurosurgery at Mayo Clinic Arizona, spoke at the 2024 American Epilepsy Society Annual Meeting on cell therapy approaches for epilepsy, the challenges the clinical community faces, and the outlook for the future. 
  • Check out the full episode here: https://www.neurologylive.com/view/episode-130-promise-behind-cell-therapy-approaches-epilepsy
    
  
  
  


• 
  Lawrence Robinson, MD, a senior scientist at Sunnybrook Research Institute, gives insight on educating the next generation of neuromuscular and electrodiagnostic (EDX) practitioners, and the major differences in how this generation of medical students learn relative to previous ones. 
  • Check out the full episode here: https://www.neurologylive.com/view/episode-127-adapting-neuromuscular-electrodiagnostic-medicine-education-modern-learners
    
  
  
  

• 
  1:05 – Ontaneda on the incorporation of new biomarkers into the 2024 McDonald Criteria for multiple sclerosis.


• 
  7:35 – Kremer on the lessons learned from drug development, including antiamyloid treatments, and initial reaction to the discontinuation of aducanumab for AD. 


• 
  10:30 – Berkowski on the outlook of treating and preventing restless legs syndrome going forward using the newly updated American Academy of Sleep Medicine treatment guidelines. 


• 
  13:10 – Husain-Wilson on the function of the Syn-One test for Parkinson disease, its applicability, and how it may distinguish patients with PD from other synucleinopathies.


• 
  18:40 – Parker on the promise and thought process behind stem cell approaches for drug-resistant epilepsy, including the different types of cell methods being tested. 


• 
  21:45 – Robinson on the distinct differences in learning styles based on generation, the importance of adaptive teaching, and the new approaches educators in neuromuscular and electrodiagnostic medicine can take. 

Episode: https://audioboom.com/posts/8627576

Podcast: https://audioboom.com/channels/5001429-neurologylive-mind-moments